References
- Canadian Cancer SocietyBreast cancer statistics Available from: http://www.cancer.ca/en/cancer-information/cancer-type/breast/statistics/?region=nbAccessed November 21, 2012
- ChungCTCarlsonRWGoals and objectives in the management of metastatic breast cancerOncologist2003851452014657529
- Early Breast Cancer Trialists’ Collaborative GroupEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet20053651687171715894097
- RiveraEManagement of metastatic breast cancer monotherapy options for patients resistant to anthracyclines and taxanesAm J Clin Oncol20103317618519675449
- Capecitabine (Xeloda®) product monograph Available from: http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=61873&lang=engAccessed November 21, 2014
- AprileGMazzerMMorosoSPuglisiFPharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancerAnticancer Drugs20092021722919247178
- ToiMAtiqur RahmanMBandoHChowLWThymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatmentLancet Oncol2005615816615737832
- SchüllerJCassidyJDumontEPreferential activation of capecitabine in tumor following oral administration to colorectal cancer patientsCancer Chemother Pharmacol20004529129710755317
- LeeSJChoiYLParkYHThymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancerCancer Chemother Pharmacol20116874375121170649
- BudmanDRMeropolNJReignerBPreliminary studies of a novel oral fluoropyrimidine carbamate: capecitabineJ Clin Oncol199816179518029586893
- KamoshidaSShiogamaKShimomuraRImmunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancerOncol Rep2005141223123016211289
- QuiddeJArnoldDSteinAClinical management of localized colon cancer with capecitabineClin Med Insights Oncol2012636337323170068
- El OmariKBronckaersALiekensSPérez-PérezMJBalzariniJStammersDKStructural basis for non-competitive product inhibition in human thymidine phosphorylase: implications for drug designBiochem J200639919920416803458
- YuEJLeeYRhaSYAngiogenic factor thymidime phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinomaMol Cancer Res200861554156618922971
- TeoNBShokerBSJarvisCSloaneJPHolcombeCThymidine phosphorylase expression and stromal vascularity in ductal carcinoma in situ of the breastJ Clin Pathol20035691992314645350
- NagaokaHIinoYTakeiHMorishitaYPlatelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumour angiogenesis and prognosis in invasive breast cancerInt J Oncol1998134494549683777
- YonenagaFTakasakiTOhiYThe expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor is correlated to angiogenesis in breast cancerPathol Int1998488508569832053
- EngelsKFoxSBWhitehouseRMGatterKCHarrisALUp-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinoma in situ of the breastJ Pathol19971824144209306962
- ErkusMMeteogluICulhaciNMeydanNErdogduIDoes thymidine phosphorylase correlate with angiogenesis in intraductal cancinoma of the breast?Saudi Med J2006271329133316951768
- LeeAHDublinEABobrowLGAngiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breastJ Pathol199918728529010398080
- YangQBarbareschiMMoriIPrognostic value of thymidine phosphorylase expression in breast carcinomaInt J Cancer20029751251711802215
- NakajimaYMadhyasthaRMaruyamaM2-Deoxy-D-ribose, a downstream mediator of thymidine phosphorylase, regulates tumor angiogenesis and progressionAnticancer Agents Med Chem2009923924519199868
- ToiMBandoHHoriguchiSModulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancerBr J Cancer2004902338234315150550
- TwelvesCVision of the future: capecitabineOncologist20016Suppl 4353911585973
- MagnéNFischelJLDubreuilAZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity rational basis for a new combination therapy with capecitabineClin Cancer Res200394735474214581344
- Ait-TihyatyMRachidZMihalcioiuCJean-ClaudeBJInhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5′-DFUR, the bioactive metabolite of Xeloda®Breast Cancer Res Treat201213321722621915635
- Ait-TihyatyMRachidZLarroque-LombardA-LJean-ClaudeBJZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activityInvest New Drugs2013311409142323959266
- BronckaersAGagoFBalzariniJLiekensSThe dual role of thymidine phosphorylase in cancer development and chemotherapyMed Res Rev20092990395319434693
- CiccoliniJEvrardACuqPThymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde storyCurr Med Chem Anticancer Agents20044718115032715
- SaitoKKhanKYuSZThe predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancerLaryngoscope2009119828819117293
- TakebayashiYAkiyamaSAkibaSClinicopathologic and prognostic significance of an human angiogenic factor, thymidine phosphorylase, in human colorectal carcinomaJ Natl Cancer Inst199688111011178757190
- GaoJLuMYuJWLiYYShenLThymidine phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxelBMC Cancer20111117721586171
- LuMGaoJWangXCShenLExpressions of thymidylate synthase, thymidine phosphorylase, class III β-tubulin, and excision repair cross-complementing group 1 predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatinChin J Cancer Res20112328829423358102
- MorelANMehtaSTaylorMARelationship of capecitabine response to thymidine phosphorylase expression and overall survival in advanced breast cancerCancer Res20107024 Suppl 2P2-09-24
- LiHSuoZZhangYThe prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomasHistol Histopathol20041912913614702180
- TominagaTToiMAbe O; 5′-BC Study GroupPrognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patientsClin Breast Cancer20023556412020396
- PuglisiFCardellinoGGCrivellariDThymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancerAnn Oncol2008191541154618441329
- HammondMEHayesDFDowsettMAmerican Society of Clinical Oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerArch Pathol Lab Med2010134e48e7220586616
- SauterGLeeJBartlettJMSlamonDJPressMFGuidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerationsJ Clin Oncol2009271323133319204209
- WolffACHammondMESchwartzJNAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerJ Clin Oncol20072511814517159189
- TsudaHAkiyamaFKurosumiMSakamotoGReproducible immunohistochemical criteria based on multiple raters’ judgements for expression of thymidine phosphorylase in breast cancer tissueBreast Cancer Res Treat20048621522315567938
- JalavaPKuopioTJuntti-PatinenLKotkansaloTKronqvistPCollanYKi67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic indexHistopathology20064867468216681683
- CheangMCChiaSKVoducDKi67 index, HER2 status, and prognosis of patients with luminal B breast cancerJ Natl Cancer Inst200910173675019436038
- WeigelMTDowsettMCurrent and emerging biomarkers in breast cancer: prognosis and predictionEndocr Relat Cancer201017R245R26220647302
- JonatWArnoldNIs the Ki67 labelling index ready for clinical use?Ann Oncol20112250050221343384
- DowsettMDunbierAKEmerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancerClin Cancer Res2008148019802619088018
- FaschingPAHeusingerKHaeberleLKi67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatmentBMC Cancer20111148622081974
- UmemuraSShiraneMTakekoshiSTokudaYMoriKOsamuraRYHigh expression of thymidine phosphorylase in basal-like breast cancers: stromal expression in EGFR- and/or CK5/6-positive breast cancersOncol Lett2010126126622966291
- AndreettaCPuppinCMinisiniAThymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancerAnn Oncol20092026527118765464
- BeckAEtienneMCChėradameSA role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracilEur J Cancer199430A151715227833111
- EtienneMCChėradameSFischelJLResponse to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activityJ Clin Oncol199513166316707602356
- IshikawaTSekiguchiFFukaseYSawadaNIshitsukaHPositive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenograftsCancer Res1998586856909485021
- TakayamaTMugiyaSSugiyamaTHigh levels of thymi-dine phosphorylase as an independent prognostic factor in renal cell carcinomaJpn J Clin Oncol20063656456916861722